Abstract In silico, defined in analogy to in vitro and in vivo as those studies that are performed on a computer, is an essential step in problem-solving and product development in classical engineering fields. The use of in silico models is now slowly easing its way into medicine. In silico models are already used in orthopaedics for the planning of complicated surgeries, personalised implant design and the analysis of gait measurements. However, these in silico models often lack the simulation of the response of the biological system over time. In silico models focusing on the response of the biological systems are in full development. This review starts with an introduction into in silico models of orthopaedic processes. Special attention is paid to the classification of models according to their spatiotemporal scale (gene/protein to population) and the information they were built on (data vs hypotheses). Subsequently, the review focuses on the in silico models used in regenerative orthopaedics research. Contributions of in silico models to an enhanced understanding and optimisation of four key elements-cells, carriers, culture and clinics-are illustrated. Finally, a number of challenges are identified, related to the computational aspects but also to the integration of in silico tools into clinical practice.
Introduction
In silico is defined, in analogy to in vitro and in vivo, as those studies that are performed on a computer or via computer simulation. The in silico dimension has long since obtained a solid place in traditional engineering sectors such as chemical engineering, automobile engineering and aviation engineering. A very illustrative example of the latter is the Boeing 777 which has become famous for being the first jetliner to be 100 % digitally designed. Throughout the design process, the aeroplane was "preassembled" on the computer, eliminating the need for a costly, full-scale mock-up. Furthermore, digital mechanical engineers were programmed to simulate all maintenance operations, thereby allowing bottlenecks to be checked that would normally only have appeared after the aeroplane would have been taken into service (http://bits.me. berkeley.edu/me39c/Spring97/Projects/b777/catia.html). This new design process allowed an aeroplane to be constructed that met the demands of various end users (not only aviation companies but also pilots, maintenance engineers, etc.), significantly reduced the problems (and associated costs) during the assembly phase [1] and led to faster approval by competent authorities resulting in a fast customer uptake. Patients are not aeroplanes, or cars or chemical plants. But the idea behind in silico medicine is similar as for any engineering sector: to use all available information, assemble a computer model and design strategies to optimise the processes under scrutiny.
In silico medicine is not new; in fact, it is already used in orthopaedics in various ways. Surgical planning software for example, taking into account the patient's anatomy through the use of medical images, allows one to carefully plan a surgery beforehand, to make sure that the identified strategy is executable (in terms of access to the sites, mechanical properties of available bone grafts, etc.) [2] and to develop patient-specific surgical guides [3, 4] . Another example is the design of custom-made implants for patients in which standard procedures cannot be used [5] . A final example are the models used in the gait analysis laboratory that are increasingly being incorporated into diagnosis and revalidation [6] . What all the above examples of in silico orthopaedics have in common however is their static nature. They allow one to assess the situation at the moment of imaging and model building, but they do not provide a prediction of the evolution of the pathology or the treatment.
A wide variety of in silico models of dynamic orthopaedic processes has been and is being developed, but their uptake in clinical practice is only in its infancy. This review focuses on the in silico models capturing the (spatio) temporal dynamics of orthopaedic processes (which will henceforth be denominated simply as 'in silico models' or 'models'). This review is by no means an exhaustive listing of all available in silico models in (regenerative) orthopaedics; it merely aims to provide an introduction to the vocabulary and potential applications of this rapidly evolving and promising field of research.
Classification of in silico models by length scales and information content
When discussing the wide variety of in silico models of biomedical processes, models are classified based on a specific aspect. Typical model classifications are based on length (and time) scale of the processes described in the model (from the gene/protein up to the population level) or on the information that has been used to build the model (from datadriven to hypothesis-driven). As an introduction to in silico orthopaedics in general, in this section, we will discuss both classifications and give examples. In the next section, we will then use the terms introduced in this section when describing in silico models for regenerative orthopaedics. Throughout this review, a number of terms specific for in silico modelling will be used regularly. Table 1 provides the definition of some commonly used terms.
The most widely used classification for in silico models is based on the length (and time) scale of the processes described in the model. Figure 1 shows a classical overview of various model systems working at different spatiotemporal scales. At the smallest time scales, the models looking at genes, proteins and the regulatory networks can be found. The models at this level aim to investigate amongst others the activation under various experimental conditions [7, 8] , the complex interplay between the different biological pathways, the attractor basins of a given network or the robustness of the network (as reviewed by [9] for developmental biology). One scale higher, at the cell level, the developed models focus on a single cell or a cluster of cells in terms of its mechanical or biological behaviour (or both). Krinner et al. [10] used a single cellbased modelling framework (in which a single cell is represented as a spherical object with certain mechanical characteristics) to investigate growth dynamics during cell culture. By giving the cells certain biological variables, phenomena such as cell differentiation and the influence of ageing on stemness can be studied in silico [11] . Models situated at the tissue level tend to represent cells, extracellular matrix (ECM) and growth factors by concentrations or densities (in weight of growth factors per volume or amount of cells per volume). A large body of literature exists describing the use of tissue level in silico models for simulation of bone biology and regeneration as reviewed in [12] [13] [14] . Typically, these models focus on a specific aspect of the fracture healing process such as mechanical loading, soluble growth factors or angiogenesis. Models focusing on angiogenesis during fracture healing often combine the cell level with the tissue level in so-called hybrid models [15, 16] . This allows for each biological variable to be represented in a manner that most closely corresponds to the physical reality, being densities for ECM and individual blood vessels for the angiogenesis aspects. Another level higher is the organ level. Here we look at the whole bone, for instance, how it behaves under mechanical loading or how damage influences its behaviour and remodelling process [17, 18] . Fracture risk for osteoporosis patients is calculated using organ level models [19] . Expanding this view to include the whole skeleton and musculature is done in patient level models. Gait analysis models serve as an input for the prediction of bone remodelling [20] and pathology development such as osteoarthritis [21] . The models developed for one patient can subsequently be used to simulate the behaviour of an entire patient population. Applying targeted variations to the parameter sets allows one to test a wide range of 'virtual patients' [22] . In silico clinical trials can then be carried out prior to (or during) in vivo clinical trials [23] [24] [25] , allowing for a better stratification of patients and a reduction in resources and time needed.
As touched upon already, some models cut across these length/time scales and combine processes at multiple levels. These models are called multiscale models. Though they can be very powerful in capturing emergent behaviour (behaviour at a specific length scale caused by phenomena taking place at another length scale), they also require even more parameters (in addition to the parameters for each level, there are the parameters related to the linking of the different scales) and carefully designed implementation techniques in order to ascertain correct results from the computational point of view.
Another classification often used is based on the information content of the models (Table 1) . Empirical models work only with the experimental data. No mechanistic assumptions are made on how the observed phenomena came about (hence the name 'phenomenological' models). Empirical modelling is well suited to discover biomarkers in large data sets [29, 30] linking e.g. in vitro observations to desired in vivo behaviour [31] . In order to capture the effects of interacting pathways on the behaviour of cells, simple network models can be used. An example of such a simple network model is a Boolean model, representing variables as either 'on' (active, 1) or 'off' (inactive, 0), allowing one to add a dynamical component to the models without increasing the number of parameters. Boolean network models can be used to investigate the robustness and attractor basins of the networks, and to identify missing links (additional variables that need to be added to the network in order to reproduce experimentally observed behaviour) [26, 32] . What is missing in these simple network models are the complex biochemical mechanisms that underlie the activation or inhibition as well as true spatiotemporal and quantitative information. This kind of information is present in mechanistic, hypothesis-driven models. These models start from the hypotheses that have been formulated to explain specific observations (whether of chemical, physical or biological origin). By translating these hypotheses into mathematical models and comparing the simulation results with the experimental results, the correctness and completeness of the hypotheses can be verified [33] . As these models often have a large set of parameters for which experimental values cannot always be determined, they are mainly used in a conceptual way. Performing in silico experiments that would be too consuming in terms of resources or time or that would ethically be unfeasible is one of the major usages for these types of models (Table 2 ).
Application to regenerative orthopaedics
In regenerative medicine in general, and regenerative orthopaedics in particular, the diamond concept has been introduced identifying four key elements for a successful therapy [34, 35] : cells, carriers, growth factor and appropriate mechanical conditions. Recently, the diamond concept was extended to the pentaconcept [36] stating that sufficient blood supply is also essential for a positive therapeutic result. For each of these key elements, a large body of (experimental) work can be found in the literature. For each of these elements, in silico models can increase the understanding of the biomedical processes at hand and can subsequently be used to design strategies to optimise that particular element in order to obtain the desired in vitro or in vivo outcome. For the purpose of this review, we have grouped the key elements into four essential building blocks in a tissue engineering (TE) strategy, namely cells (with or without growth factors), carriers, culture (with or without growth factors or mechanics) and clinics (combining mechanics and vascularisation) (Fig. 2) . The models vary in length scale and information content (cf. previous section), depending on the particular research/clinical question at hand.
For the cell compartment, the main goal in regenerative orthopaedics is to obtain robust cell sources with a Fig. 1 Classification of in silico models by length scale. Gene/protein: gene regulatory network for chondrogenic differentiation [26] . Cell: cell expansion influenced by the mechanical properties of the microbead (colour scale indicates mechanical state of cell) [27] . Tissue: blood vessel (red) and bone tissue (black) formation in a murine fracture [15] . Organ: bone remodelling in proximal femur [18] . Patient: assessment of musculoskeletal system during crouching [28] reproducible and predictable in vitro and in vivo behaviour. Empirical models based on extensive data sets, such as the ones developed by [30, 39] , allow for the identification of the biological state of a cell and the distillation of a limited number of functional regulators indicative of the biological process in vitro and in vivo [29, 31, 40] . Mechanistic models using knowledge of specific relevant pathways allow one to investigate the dynamics of the cell state when specific growth factors are used during cell culture [41, 42] . Yet other models investigate the regulatory networks and the basins of attraction of specific cell states, providing insight into precise culture conditions that push or keep cells in the desired state [26, 43] . An example of the latter is the work by Kerkhofs et al. [26] who created a large-scale literature-based Boolean model of the osteochondral regulatory network (Fig. 2, bottom right) . Using this model, the authors investigated the influence of activating or suppressing several genes in this network on the cell's capacity to progress through the endochondral ossification process. This activation or suppression can subsequently be translated into composition of culture media for in vitro cell culture.
Models focusing on the carriers focus on the mechanical [27, [44] [45] [46] , chemical [47] [48] [49] [50] and/or morphological aspects [51] [52] [53] [54] of the carrier with the aim of understanding their influence on the behaviour of the seeded cells and subsequently optimising their design. Smeets et al. [27] used an individual cell-based model to investigate the influence of the stiffness of microcarriers on the proliferation of the cells seeded onto it (Fig. 1, cell level) . Another example is the work of Carlier et al. [37] who used a mechanistic model of bone formation in calcium phosphate containing biomaterials. Based on a combination of experimental data and hypotheses put forward by experimental collaborators, the model is able to capture the different aspects of the calcium phosphatedriven bone formation process. The model is subsequently used to design combinations of cell seeding densities (or other cell properties such as growth rate) and calcium release rates yielding optimal bone formation (Fig. 2, bottom left) .
As reported on several occasions, bioreactor culture can be an important step in the TE product development cycle, allowing a reduction of the product variability [55] [56] [57] . A plethora of bioreactor set-ups are available on the market, from complete industrially developed closed systems to modular research variants. More and more the in silico models discussed above are combined with a description of the physical environment that the bioreactor presents to the TE product during the in vitro culture process (in terms of e.g. fluid flow, mechanical stimulation and mass transport). Optimisation of initial cell seeding and initial cellular differentiation is predicted through the adaptation of the bioreactor protocol and scaffold morphology [43, 58, 59 ] (see also [60] and references within). Additionally, neotissue growth during extended culture of the TE products can be captured by multiphysics models combining a description of the physical bioreactor environment with a (mechanistic) description of cellular behaviour and matrix production [61] [62] [63] . Guyot and co-authors used a description of curvature-based cell growth in combination with a detailed model of a perfusion bioreactor system. The combined multiphysics modelling platform has been used to optimise the location of the TE construct inside the bioreactor increasing product homogeneity and quality [55] and to screen various scaffold designs for optimal neotissue growth [38] . Once validated, these multiphysics models can become an inherent part of the bioreactor control loop, providing an insightful view into the TE product in culture by allowing one to liaise the bioreactor sensor read-outs (e.g. pressure drop) with the biological interpretation in terms of local neotissue growth in the TE product.
Finally, the host environment (denoted clinic in Fig. 2 ) is a crucial component of the TE design strategy, and the ability to predict the interaction between the host and the TE product is pivotal for many of the biological processes in regenerative orthopaedics. In silico models allow one to combine knowledge on basic biology and TE product behaviour to study the effect of e.g. in vivo scaffold dissolution on local in vivo cell biology [37, 53] and blood vessel formation [59, 64] . Patients presenting with structurally and/or genetically challenged healing environments pose additional challenges to the TE strategy, but it is most often in those patients that normal healing is impaired and thus TE solutions are required. In silico models are applied both to study the aetiology of impaired healing [16, 33] and to design novel therapeutic strategies that are able to overcome the additional patient-specific hurdles [33] . These models provide an additional level of (mechanistic) understanding to the data-driven empirical models which use multi-parametric techniques to link in vitro characteristics (biomarkers) to observed in vivo behaviour (such as in classical genomics studies).
Future perspectives
Today, the use of these dynamical models in clinical practice is still limited; however, their usage as a research tool in academia and industry is growing steadily [65] . In fields such as cancer and cardiac disease, computational models are directly responsible for the development of novel treatment strategies which are currently being tested in phase I and II clinical trials [41] (http://clinicaltrials.gov/ct2/results?term=mm-121&1Search=Search). In diabetes, the US Food and Drug Administration (FDA) has approved the use of computational models as valid preclinical evidence for the dossier of implantable insulin pumps [66] . Furthermore, in silico modelling is explicitly mentioned as an important tool to tackle many of the FDA's 'priorities for regulatory science for medical products' [67] . Additionally, the increasing scrutiny on the ethical aspects of biomedical research involving laboratory animals provides strong incentives for in silico research. The realisation of the 3R's (reduction, refinement, replacement) is a natural consequence of the use of in silico models as an inherent part of the research pipeline. Furthermore, in silico models can assist in the translation of research findings obtained in animals to clinical opportunities in humans. The scientific community in the field of in silico medicine is benefiting from large-scale initiatives such as the Physiome (http://physiomeproject.org/) and the virtual physiological human [68] . The aim of these initiatives is not to develop one integrated model of a complete human being but rather to develop a framework in which models focusing on different organ systems and on different length/time scales can interact with each other. In order for this to happen, scientists active in the field of in silico medicine should agree on a set of standards [69] that will allow this interplay between different in silico models but also between in vitro, in vivo and in silico models. Fig. 2 Classification of in silico models by their contribution to the basic building blocks of regenerative medicine. Cell: a gene regulatory network for chondrogenic differentiation is shown, along with a comparison between experimental (pale pink) and simulation (black) results for the hypertrophic phenotype [26] . Carrier: prediction of calcium dissolution from calcium phosphate-based carrier (bottom, unpublished results, courtesy of V. Manhas) and prediction of optimal cell-carrier combinations for various initial cell densities (cm0) [37] . Culture: neotissue (green) growth in a porous titanium scaffold (grey/black) [38] . Clinics: simulation of blood vessel formation in a large defect in mice [16] The trend towards personalised and precision medicine demands an ever increasing integration of all available information on the patients, ranging from lifestyle over anatomy to genetics. The integration and interpretation of all this information can be facilitated by the use of in silico models. The vision of the virtual physiological human can have different faces depending on the users: the digital patient for clinicians [70] , the digital guinea pig for researchers, personal health forecasting for patients and in silico clinical trials for industry.
As stated in the Introduction, in silico medicine is already practised in orthopaedics; however, it is mainly restricted to the mechanical aspects of the locomotor system. The simulation of biological processes, especially in regenerative orthopaedics, is in full development. In silico medicine can only reach its full potential when its development is taken in hand not only by engineers and mathematicians but also by biomedical scientists and clinicians in an interactive and integrative way. As was the case for the Boeing 777, by involving all potential users from the start of the model development, the model's clinical validation and uptake will be strongly facilitated. The ever increasing available computational power [71] will allow for the calculation of increasingly complex computational models in real time, nurturing the further exploitation of in silico models as a valuable tool in regenerative orthopaedics.
